Mutation Analysis of Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer for Selection of Patients Eligible for Tyrosine Kinase Inhibitor Therapy

1. Bade BC, Cruz CS. Lung cancer 2020: Epidemiology, etiology, and prevention. Clin Chest Med 2020;41: 1-24. Bade BC Cruz CS. Lung cancer 2020: Epidemiology, etiology, and prevention . Clin Chest Med 2020 ; 41 : 1 - 24 . Search in Google Scholar

2. Ikram A, Pervez S, Khadim MT, Sohaib M, Uddin H, Badar F, et al. National cancer registry of Pakistan: First comprehensive report of cancer statistics 2015-2019. J Coll Physicians Surg Pak 2023;33:625-32. Ikram A Pervez S Khadim MT Sohaib M Uddin H Badar F National cancer registry of Pakistan: First comprehensive report of cancer statistics 2015-2019 . J Coll Physicians Surg Pak 2023 ; 33 : 625 - 32 . Search in Google Scholar

3. Chevallier M, Borgeaud M, Addeo M, Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future. J Clin Oncol 2021;12:217-37. Chevallier M Borgeaud M Addeo M Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future . J Clin Oncol 2021 ; 12 : 217 - 37 . Search in Google Scholar

4. Kang L, Zheng J, Zhu X. Relationship between EGFR mutations and pathological classification and specimen of lung adenocarcinoma. Chin J Cancer 2017;20:382-8. Kang L Zheng J Zhu X. Relationship between EGFR mutations and pathological classification and specimen of lung adenocarcinoma . Chin J Cancer 2017 ; 20 : 382 - 8 . Search in Google Scholar

5. Parris BA, Leong S, Marshall H, Yang IA, Fong KM, et al. Postoperative adjuvant EGFR-TKIS for resected EGFR-mutant NSCLC-opportunities and obstacles. Ann Transl Med 2021;9:586. Parris BA Leong S Marshall H Yang IA Fong KM Postoperative adjuvant EGFR-TKIS for resected EGFR-mutant NSCLC-opportunities and obstacles . Ann Transl Med 2021 ; 9 : 586 . Search in Google Scholar

6. Troncone G. All-in-one: The dream and reality of molecular cytopathology testing on routine lung cancer smears. Cancer Cytopathol 2018;126:155-7. Troncone G. All-in-one: The dream and reality of molecular cytopathology testing on routine lung cancer smears . Cancer Cytopathol 2018 ; 126 : 155 - 7 . Search in Google Scholar

7. Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR. Lung cancer diagnosed in the young is associated with enrichment for targetable genomic alterations and poor prognosis. JAMA Oncol 2016;2:313-20. Sacher AG Dahlberg SE Heng J Mach S Jänne PA Oxnard GR. Lung cancer diagnosed in the young is associated with enrichment for targetable genomic alterations and poor prognosis . JAMA Oncol 2016 ; 2 : 313 - 20 . Search in Google Scholar

8. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. Non-small cell lung cancer, version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15:504-35. Ettinger DS Wood DE Aisner DL Akerley W Bauman J Chirieac LR Non-small cell lung cancer, version 5.2017, NCCN Clinical Practice Guidelines in Oncology . J Natl Compr Canc Netw 2017 ; 15 : 504 - 35 . Search in Google Scholar

9. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500. Paez JG Jänne PA Lee JC Tracy S Greulich H Gabriel S EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy . Science 2004 ; 304 : 1497 - 500 . Search in Google Scholar

10. Beasley MB, Milton DT. ASCO provisional clinical opinion: Epidermal growth factor receptor mutation testing in practice. J Oncol Pract 2011;7:202-4. Beasley MB Milton DT. ASCO provisional clinical opinion: Epidermal growth factor receptor mutation testing in practice . J Oncol Pract 2011 ; 7 : 202 - 4 . Search in Google Scholar

11. Ahmed ZA, Moatter T, Siddiqui A, Pervez S. Distribution of EGFR mutations commonly observed in primary lung adenocarcinomas in Pakistan as predictors for targeted therapy. Asian Pac J Cancer Prev 2014;15:7125-8. Ahmed ZA Moatter T Siddiqui A Pervez S. Distribution of EGFR mutations commonly observed in primary lung adenocarcinomas in Pakistan as predictors for targeted therapy . Asian Pac J Cancer Prev 2014 ; 15 : 7125 - 8 . Search in Google Scholar

12. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. Lynch TJ Bell DW Sordella R Gurubhagavatula S Okimoto RA Brannigan BW Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib . N Engl J Med 2004 ; 350 : 2129 - 39 . Search in Google Scholar

13. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci 2004;101:13306-11. Pao W Miller V Zakowski M Doherty J Politi K Sarkaria I EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib . Proc Natl Acad Sci 2004 ; 101 : 13306 - 11 . Search in Google Scholar

14. Li X, Wei S, Deng L, Tao H, Liu M, Zhao Z, et al. Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific. BMC Pulm Med 2023;23:99. Li X Wei S Deng L Tao H Liu M Zhao Z Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific . BMC Pulm Med 2023 ; 23 : 99 . Search in Google Scholar

15. Han B, Tjulandin S, Hagiwara K, Normanno N, Wulandari L, Laktionov K, et al. EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. Lung Cancer 2017;113:37-44. Han B Tjulandin S Hagiwara K Normanno N Wulandari L Laktionov K EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study . Lung Cancer 2017 ; 113 : 37 - 44 . Search in Google Scholar

16. Benbrahim Z, Antonia T, Mellas N. EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: A systematic review and meta-analysis. BMC Cancer 2018;18:891. Benbrahim Z Antonia T Mellas N. EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: A systematic review and meta-analysis . BMC Cancer 2018 ; 18 : 891 . Search in Google Scholar

17. Noronha V, Prabhash K, Thavamani A, Chougule A, Purandare N, Joshi A, et al. EGFR mutations in Indian lung cancer patients: Clinical correlation and outcome to EGFR targeted therapy. PLoS One 2013;8:e61561. Noronha V Prabhash K Thavamani A Chougule A Purandare N Joshi A EGFR mutations in Indian lung cancer patients: Clinical correlation and outcome to EGFR targeted therapy . PLoS One 2013 ; 8 : e61561 . Search in Google Scholar

18. Rahman S, Kondo N,Yoneda K, Takuwa T, Hashimoto M, Orui H, et al. Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma of the lung. Int J Clin Oncol 2014;19:45-9. Rahman S Kondo N Yoneda K Takuwa T Hashimoto M Orui H Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma of the lung . Int J Clin Oncol 2014 ; 19 : 45 - 9 . Search in Google Scholar

19. Wu SG, Chang YL, Yu CJ, Yang PC, Shih JY. Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. ERJ Open Res 2017;3:00092-2016. Wu SG Chang YL Yu CJ Yang PC Shih JY. Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors . ERJ Open Res 2017 ; 3 : 00092 - 2016 . Search in Google Scholar

20. Esteban E, Majem M, Aguillo MM, Banaclocha NM, Dómine M, Aldaravi LG, et al. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. Cancer Epidemiol 2015;39:291-7. Esteban E Majem M Aguillo MM Banaclocha NM Dómine M Aldaravi LG Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study . Cancer Epidemiol 2015 ; 39 : 291 - 7 . Search in Google Scholar

21. Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T, et al. Treatment of uncommon EGFR mutations in non-small cell lung cancer: New evidence and treatment. Transl Lung Cancer Res 2019;8:302-16. Zhang T Wan B Zhao Y Li C Liu H Lv T Treatment of uncommon EGFR mutations in non-small cell lung cancer: New evidence and treatment . Transl Lung Cancer Res 2019 ; 8 : 302 - 16 . Search in Google Scholar

22. Hsu WH, Yang JH, Mok TS, Loong HH. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol 2018;29:i3-9. Hsu WH Yang JH Mok TS Loong HH. Overview of current systemic management of EGFR-mutant NSCLC . Ann Oncol 2018 ; 29 : i3 - 9 . Search in Google Scholar

23. Chiu CH, Yang CT, Shih JY, Huang MS, Su WC, Lai RS, et al. Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations. J Thorac Oncol 2015;10:793-9. Chiu CH Yang CT Shih JY Huang MS Su WC Lai RS Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations . J Thorac Oncol 2015 ; 10 : 793 - 9 . Search in Google Scholar

24. Suda K, Onozato R, Yatabe Y, Mitsudomi T. EGFR T790M mutation: A double role in lung cancer cell survival? J Thorac Oncol 2009;4:1-4. Suda K Onozato R Yatabe Y Mitsudomi T. EGFR T790M mutation: A double role in lung cancer cell survival? J Thorac Oncol 2009 ; 4 : 1 - 4 . Search in Google Scholar

25. Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA, et al. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 2007;67:2325-30. Mulloy R Ferrand A Kim Y Sordella R Bell DW Haber DA Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib . Cancer Res 2007 ; 67 : 2325 - 30 . Search in Google Scholar

26. Wei Z, An T, Wang Z, Chen K, Bai H, Zhu G, et al. Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors. Thorac Cancer 2014;5:126-32. Wei Z An T Wang Z Chen K Bai H Zhu G Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors . Thorac Cancer 2014 ; 5 : 126 - 32 . Search in Google Scholar

27. Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 2012;30:433-40. Su KY Chen HY Li KC Kuo ML Yang JC Chan WK Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer . J Clin Oncol 2012 ; 30 : 433 - 40 . Search in Google Scholar